Canine mammary tumor (CMT) is prevalent in dogs, which severely threatens dogs’ life and health due to the limitations of treatment except for surgery. Growing evidences demonstrate that long noncoding RNAs (lncRNAs) play a critical role in multiple cancer progression. Here, we focused on a novel lncRNA downregulated by doxorubicin to explore its functions and underlying mechanism. First, a significantly high expression of lncRNA 28672 was observed in clinical CMT tissues. Subsequently, functional experiments demonstrate that overexpression of lncRNA 28672 significantly promoted the growth and metastasis of CMT cells, and the growth of tumors in xenograft models. Finally, mechanistic studies reveal that lncRNA 28672 upregulates the expression of H2BC11 and activates the JAK1/STAT1 pathway. Collectively, lncRNA 28672 acts as an oncogene that drives CMT progression specifically by activating the JAK1/STAT1 pathway, which may serve as a potential diagnostic biomarker and a targeted therapeutic agent for the treatment of CMTs.

To Cite This Article: Diao H, Zhang Y, Chen S, Tao Q, Zhang Y, Liu S, Yan S and Su R, 2026. lncRNA 28672 facilitates canine mammary tumor progression and is associated with H2BC11 expression and JAK1/STAT1 activation. Pak Vet J, 46(3): 653-661. http://dx.doi.org/10.29261/pakvetj/2026.054